Gareth Wakefield
Fondateur chez Xerion Healthcare Ltd.
Profil
Gareth Wakefield is the founder and currently holds the position of Director & Chief Technical Officer at Xerion Healthcare Ltd., which he founded in 2015.
He previously worked as a Group Manager-Particle Technologies at DeepMatter Group Plc.
Dr. Wakefield obtained a doctorate degree from the University of Bristol.
Postes actifs de Gareth Wakefield
| Sociétés | Poste | Début |
|---|---|---|
Xerion Healthcare Ltd.
 Xerion Healthcare Ltd. BiotechnologyHealth Technology Xerion Healthcare Ltd. develops and commercializes nanoparticle treatment to cure head, and neck and lung cancer. It injects Nanoparticles into tumours and generates free radicals by splitting water rather than interacting with oxygen. The firm’s nanoparticles are based on titanium dioxide, a common, non-toxic, semiconductor material. The company was founded by Gareth Wakefield and Helen Townley in 2015 and is headquartered in Thame, the United Kingdom. | Fondateur | 01/01/2015 |
Anciens postes connus de Gareth Wakefield
| Sociétés | Poste | Fin |
|---|---|---|
| DEEPMATTER GROUP PLC | Corporate Officer/Principal | - |
Formation de Gareth Wakefield
| University of Bristol | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
DeepMatter Group Plc
 DeepMatter Group Plc Packaged SoftwareTechnology Services DeepMatter Group Plc is engaged in the development of a number of projects targeting new chemicals, materials, formulations, and pharmaceuticals in commercial areas. It operates through the following segments: DeepMatter and InfoChem. The DeepMatter segment owns, develops and is in the early stage of exploiting intellectual property, software, hardware and data analysis capabilities combined as a visionary, disruptive platform called DigitalGlassware, enabling step changes in productivity and discovery for scientists in the pharma and life science sectors. The InfoChem segment develops and commercialises cheminformatics software to handle, store and retrieve chemical structures and reactions for application in pharma, life sciences, and scientific publications. The company was founded by Jon-Paul Griffiths and Mark G. Moloney on June 13, 2006 and is headquartered in Glasgow, the United Kingdom. | Technology Services |
Xerion Healthcare Ltd.
Xerion Healthcare Ltd. BiotechnologyHealth Technology Xerion Healthcare Ltd. develops and commercializes nanoparticle treatment to cure head, and neck and lung cancer. It injects Nanoparticles into tumours and generates free radicals by splitting water rather than interacting with oxygen. The firm’s nanoparticles are based on titanium dioxide, a common, non-toxic, semiconductor material. The company was founded by Gareth Wakefield and Helen Townley in 2015 and is headquartered in Thame, the United Kingdom. | Health Technology |
